Novartis AG (VTX:NOVN) Given a CHF 82 Price Target at S&P Global

Novartis AG (VTX:NOVN) has been given a CHF 82 target price by equities researchers at S&P Global in a research report issued on Tuesday. The brokerage presently has a “neutral” rating on the stock.

Other equities analysts have also issued research reports about the company. Jefferies Group LLC set a CHF 100 target price on Novartis AG and gave the stock a “buy” rating in a research report on Monday, May 29th. HSBC Holdings plc set a CHF 85 target price on Novartis AG and gave the stock a “buy” rating in a research report on Wednesday, June 21st. Kepler Capital Markets set a CHF 88 target price on Novartis AG and gave the stock a “buy” rating in a research report on Tuesday, July 4th. Deutsche Bank AG set a CHF 78 target price on Novartis AG and gave the stock a “neutral” rating in a research report on Wednesday, June 21st. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 target price on Novartis AG and gave the stock a “neutral” rating in a research report on Wednesday, June 21st. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of CHF 83.71.

Shares of Novartis AG (NOVN) opened at 81.20 on Tuesday. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 84.35. The stock has a 50 day moving average of CHK 79.91 and a 200 day moving average of CHK 76.50.

ILLEGAL ACTIVITY WARNING: This report was originally reported by BBNS and is the property of of BBNS. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://baseballnewssource.com/markets/novartis-ag-vtxnovn-given-a-chf-82-price-target-at-sp-global/1233861.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.